ACS Antithrombotic Selection

Treat patients with ACS using initial antiplatelet therapy plus parenteral anticoagulation while defining the revascularization plan. In patients without a separate indication for long-term oral anticoagulation, discontinue anticoagulation after the acute hospitalization rather than continuing it as routine secondary prevention. Oxford AcademicOxford Academic‘10 commandments’ for the 2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic

Send NSTE-ACS directly to immediate invasive coronary angiography when any very-high-risk feature is present: hemodynamic instability or cardiogenic shock, recurrent or ongoing chest pain refractory to medical therapy, acute heart failure thought due to ongoing ischemia, life-threatening arrhythmia or cardiac arrest after presentation, mechanical complication, or recurrent dynamic ischemic ECG changes. These features override routine biomarker-based observation. Oxford AcademicOxford Academic‘10 commandments’ for the 2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic

For NSTE-ACS without an immediate angiography indication, use a validated 0/1-hour or 0/2-hour NSTEMI rule-in/rule-out algorithm. Pursue angiography within 24 hours when NSTEMI is confirmed, GRACE score exceeds 140, transient ST-segment elevation occurs, or dynamic ST-segment/T-wave changes are present. Oxford AcademicOxford Academic‘10 commandments’ for the 2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic

Do not routinely pretreat a patient with NSTE-ACS with an oral P2Y12 inhibitor when an early invasive strategy is planned and coronary anatomy is not yet known. This avoids committing the patient to potent platelet inhibition before defining PCI need, CABG candidacy, or a noncoronary diagnosis. ACC+1ACC2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations - American College of CardiologyACC2020 ESC NSTE-ACS Guidelines: Evolving Approaches and ...

For ACS after coronary stent implantation, ticagrelor is reasonable in preference to clopidogrel for maintenance P2Y12 therapy. Contemporary guidance continues to frame DAPT with aspirin plus ticagrelor or prasugrel as the standard antiplatelet approach for many ACS patients during the first year, particularly when bleeding risk is not high. ACC+2ACC2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesjaccDe-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary SyndromesjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

Do not administer prasugrel to a patient with prior stroke or TIA. For patients aged 75 years or older or weighing less than 60 kg, consider reducing the prasugrel maintenance dose; these two characteristics should prompt an explicit reassessment of whether prasugrel's ischemic benefit justifies bleeding exposure. jaccjaccAntiplatelet and Anticoagulant Therapy in the 2025 ACC ...

Use clopidogrel as the preferred P2Y12 inhibitor when chronic oral anticoagulation is required after PCI. Clopidogrel is also a reasonable alternative when bleeding risk, adverse effects, or cost limit ticagrelor or prasugrel, including in older patients. jacc+1jacc2025 Acute Coronary Syndromes Guideline-at-a-Glance | JACCjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

In POPular AGE, patients aged 70 years or older with NSTE-ACS assigned to clopidogrel had noninferior outcomes compared with ticagrelor or prasugrel; the trial population had a mean age of 77 years. This evidence supports clopidogrel selection when advanced age and bleeding susceptibility outweigh the anticipated incremental ischemic protection from a potent P2Y12 inhibitor. The Lancet+1The LancetClopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trialjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

For ACS patients who are not at high bleeding risk, prescribe DAPT for at least 12 months. Use low-dose aspirin during DAPT; the ACC/AHA focused update recommends 81 mg daily, with an acceptable range of 75 to 100 mg daily. ACC+1ACC2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

For a patient who has tolerated ticagrelor-based DAPT after PCI and in whom bleeding reduction is a priority, transition to ticagrelor monotherapy no earlier than 1 month after PCI. This pathway preserves potent P2Y12 inhibition while removing aspirin exposure. jacc+1jacc2025 Acute Coronary Syndromes Guideline-at-a-Glance | JACCjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

Do not equate all abbreviated regimens. Current commentary on the 2025 guideline states that abbreviated clopidogrel or prasugrel monotherapy is not recommended after ACS PCI: shorter clopidogrel regimens have increased MI compared with 12-month treatment, and abbreviated prasugrel-monotherapy safety remains inconclusive. jaccjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

If a patient initially receives ticagrelor or prasugrel, reassess at 1 month for clinically important bleeding, drug intolerance, or unaffordability. A switch to clopidogrel after 1 month may be considered, but frame it as a tradeoff with less robust evidence for ischemic equivalence than standard therapy. jaccjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

In ACS patients undergoing PCI who require long-term oral anticoagulation, discontinue aspirin 1 to 4 weeks after PCI and continue the oral anticoagulant plus a P2Y12 inhibitor, preferably clopidogrel. This is the preferred U.S. guideline pathway for reducing ongoing bleeding exposure while maintaining antithrombotic protection. jacc+1jacc2025 Acute Coronary Syndromes Guideline-at-a-Glance | JACCjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

A short triple-therapy interval may be used for 7 to 30 days, followed by oral anticoagulation plus clopidogrel. In the AUGUSTUS population of patients with atrial fibrillation and recent ACS or PCI receiving a planned P2Y12 inhibitor, apixaban plus a P2Y12 inhibitor reduced bleeding compared with vitamin K antagonist therapy, while aspirin increased bleeding without an overall efficacy advantage. ACC+1ACCAntithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation - American College of CardiologyjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

Use the first 30 days to individualize aspirin duration. In AUGUSTUS, aspirin versus placebo through approximately 30 days increased severe bleeding from 1.1% to 2.1% while reducing severe ischemic events from 2.6% to 1.7%; after 30 days, aspirin increased bleeding from 2.5% to 3.7% without a significant reduction in ischemic events. ACCACCAntithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation - American College of Cardiology

At discharge, document the indication for each antithrombotic agent, the intended aspirin stop date, the intended P2Y12 duration, and whether long-term oral anticoagulation is required. This prevents inadvertent prolonged triple therapy and makes the 1-month reassessment actionable. jacc+2jacc2025 Acute Coronary Syndromes Guideline-at-a-Glance | JACCACCAntithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation - American College of CardiologyjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

Escalate urgently to invasive reassessment for recurrent or ongoing ischemic chest pain refractory to medical treatment, recurrent dynamic ischemic ECG changes, acute heart failure presumed due to ongoing ischemia, hemodynamic instability, life-threatening arrhythmia, cardiac arrest, or mechanical complications. These are immediate angiography triggers even after an initially less urgent pathway. Oxford AcademicOxford Academic‘10 commandments’ for the 2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic

When bleeding occurs, first identify whether aspirin can be withdrawn under an established pathway rather than reflexively stopping all antiplatelet therapy. Ticagrelor monotherapy at 1 month or later after PCI is the guideline-supported aspirin-withdrawal option for patients who have tolerated DAPT; in patients requiring oral anticoagulation, aspirin discontinuation at 1 to 4 weeks with continued clopidogrel is preferred. jacc+1jacc2025 Acute Coronary Syndromes Guideline-at-a-Glance | JACCjaccPerspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline